CTRI/2010/091/000624Other2 期
An Open Label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia
Antisoma Research ltdChiswick Park Building 5, 566 Chiswick High Road, London, W4 5YF United Kingdom0 个研究点目标入组 90 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- Other
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing and able to provide written informed consent and in the opinion of the Investigator able to comply with the study assessments and follow-up.
- •2. Diagnosis of AML as defined by the World Health Organization (WHO) classification(Vardiman, 2009)
- •3. Primary refractory AML (defined as a failure to achieve a CR or CRi after therapy with curative intent) or AML in first relapse
- •4. ECOG performance status 0, 1 or 2
- •5. Age ≥18 and ≤ 70 years
- •6. Total bilirubin < 2 x ULN, or direct (conjugated) bilirubin < 2 x ULN
- •7. AST < 5 x ULN, ALT < 5 x ULN
- •8. Creatinine < 1.5 x ULN (or if creatinine is ≥ 1.5 times ULN, creatinine clearance > 50ml/min using the Cockcroft-Gault formula)
- •9. For patients presenting with primary refractory AML, ≥ 20% blasts on baseline bone marrow assessment
- •10. For patients presenting with relapsed AML, ≥ 5% blasts on baseline bone marrow assessment
排除标准
- •1. Unwilling to accept the required per protocol sample collection, including extra bone marrow assessments, blood sample collections
- •2. An initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976)
- •3. Secondary AML, defined as AML evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent
- •4. Clinically active CNS leukemia
- •5. White blood cell count > 20 billion/L (Patients treated with leukophoresis and/or hydroxyurea to bring down the WBC prior to study entry are not excluded)
- •6. Previously received a total cumulative dose of cytarabine > 6g/m2 in the last 6 months
- •7. Previously received> 1 induction regimen (Defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)except if a preceding CR/CRi/CRp lasted > 6 months
- •8. Known allergy to cytarabine
- •9. Pregnant or nursing
- •10. Women of childbearing potential or sexually active males unless (1) the patient is surgically sterile or 2) using adequate contraception (defined as either IUD, oral or depot contraceptive, or barrier plus spermicide) while receiving study treatment and for at least 6 months after termination of treatment . Women must be post-menopausal for at leat 2 years to be considered of non-child bearing potential
- •11. Known HIV positivity where the condition is not well managed using antiretroviral therapies
- •12. Serious uncontrolled infection rendering the patient unsuitable for high dose cytarabine treatment
- •13. Psychiatric illness or social situation that would preclude study compliance
- •14. Treatment with other investigational agents for any reason within 28 days prior to study entry
- •15. Any uncontrolled illness
- •16. Other malignancy, survival from which is anticipated to be ≤ 2 years from study entry
研究者
相似试验
尚未招募
2 期
A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic AdenocarcinomaPancreas cancerLocally Advanced Pancreatic Adenocarcinoma1001567410017991NL-OMON56480AIM ImmunoTech Inc.30
已完成
不适用
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis-B55 LeishmaniasisB55LeishmaniasisPER-158-08INFECTIOUS DISEASES RESEARCH INSTITUTE,46
进行中（未招募）
1 期
A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyEUCTR2019-003117-33-ITMILLENNIUM PHARMACEUTICALS, INC.150
进行中（未招募）
1 期
A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyAcute Myeloid Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10024330Term: Leukemia acuteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10024348Term: Leukemia myelogenousSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003117-33-PLMillennium Pharmaceuticals, Inc.150
进行中（未招募）
1 期
A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyEUCTR2019-003117-33-FRTakeda Development Center Americas, Inc.150